#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Brief Overview of the Established Practice in Determining the Amino Acid Composition of the CHO Cell Medium
1-1	0-2	2.	_	_	_	_
1-2	3-8	Brief	abstract[1]	new[1]	_	_
1-3	9-17	Overview	abstract[1]	new[1]	_	_
1-4	18-20	of	abstract[1]	new[1]	_	_
1-5	21-24	the	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-6	25-36	Established	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-7	37-45	Practice	abstract[1]|abstract[2]	new[1]|new[2]	_	_
1-8	46-48	in	_	_	_	_
1-9	49-60	Determining	_	_	_	_
1-10	61-64	the	abstract[4]	new[4]	coref	2-4[10_4]
1-11	65-70	Amino	abstract[4]	new[4]	_	_
1-12	71-75	Acid	person|abstract[4]	new|new[4]	_	_
1-13	76-87	Composition	abstract[4]	new[4]	_	_
1-14	88-90	of	abstract[4]	new[4]	_	_
1-15	91-94	the	abstract[4]|object[7]	new[4]|new[7]	_	_
1-16	95-98	CHO	abstract[4]|abstract|object[7]	new[4]|new|new[7]	coref	2-9
1-17	99-103	Cell	abstract[4]|person|object[7]	new[4]|new|new[7]	_	_
1-18	104-110	Medium	abstract[4]|object[7]	new[4]|new[7]	_	_

#Text=Reports on improving the culture medium composition for CHO cells , specifically in relation to the amino acids , are relatively limited in number .
2-1	111-118	Reports	abstract	new	coref	3-4
2-2	119-121	on	_	_	_	_
2-3	122-131	improving	_	_	_	_
2-4	132-135	the	abstract[10]	giv[10]	coref	18-40[154_10]
2-5	136-143	culture	abstract|abstract[10]	new|giv[10]	coref	15-19[124_0]
2-6	144-150	medium	abstract[10]	giv[10]	_	_
2-7	151-162	composition	abstract[10]	giv[10]	_	_
2-8	163-166	for	abstract[10]	giv[10]	_	_
2-9	167-170	CHO	abstract[10]|substance|object[12]	giv[10]|giv|new[12]	coref|coref|coref|coref	3-18|3-18[22_12]|3-18|3-18[22_12]
2-10	171-176	cells	abstract[10]|object[12]	giv[10]|new[12]	_	_
2-11	177-178	,	_	_	_	_
2-12	179-191	specifically	abstract[13]	new[13]	_	_
2-13	192-194	in	abstract[13]	new[13]	_	_
2-14	195-203	relation	abstract[13]	new[13]	_	_
2-15	204-206	to	abstract[13]	new[13]	_	_
2-16	207-210	the	abstract[13]|substance[15]	new[13]|new[15]	coref	7-30[41_15]
2-17	211-216	amino	abstract[13]|object|substance[15]	new[13]|new|new[15]	coref	7-30
2-18	217-222	acids	abstract[13]|substance[15]	new[13]|new[15]	_	_
2-19	223-224	,	_	_	_	_
2-20	225-228	are	_	_	_	_
2-21	229-239	relatively	_	_	_	_
2-22	240-247	limited	_	_	_	_
2-23	248-250	in	_	_	_	_
2-24	251-257	number	abstract	new	coref	7-22[38_0]
2-25	258-259	.	_	_	_	_

#Text=This paucity of reports is strikingly unusual especially considering the widespread use and vast economic importance of CHO cells .
3-1	260-264	This	abstract[17]	new[17]	_	_
3-2	265-272	paucity	abstract[17]	new[17]	_	_
3-3	273-275	of	abstract[17]	new[17]	_	_
3-4	276-283	reports	abstract[17]|abstract	new[17]|giv	_	_
3-5	284-286	is	_	_	_	_
3-6	287-297	strikingly	_	_	_	_
3-7	298-305	unusual	_	_	_	_
3-8	306-316	especially	_	_	_	_
3-9	317-328	considering	_	_	_	_
3-10	329-332	the	abstract[19]	new[19]	_	_
3-11	333-343	widespread	abstract[19]	new[19]	_	_
3-12	344-347	use	abstract[19]	new[19]	_	_
3-13	348-351	and	_	_	_	_
3-14	352-356	vast	abstract[20]	new[20]	_	_
3-15	357-365	economic	abstract[20]	new[20]	_	_
3-16	366-376	importance	abstract[20]	new[20]	_	_
3-17	377-379	of	abstract[20]	new[20]	_	_
3-18	380-383	CHO	abstract[20]|substance|object[22]	new[20]|giv|giv[22]	coref|coref|coref|coref	7-6|7-6[32_22]|7-6|7-6[32_22]
3-19	384-389	cells	abstract[20]|object[22]	new[20]|giv[22]	_	_
3-20	390-391	.	_	_	_	_

#Text=2.1 .
4-1	392-395	2.1	abstract	new	_	_
4-2	396-397	.	_	_	_	_

#Text=Statistical Methods : Utilizing Data-Driven Models in Experimental Design
5-1	398-409	Statistical	abstract[24]	new[24]	coref	20-9[168_24]
5-2	410-417	Methods	abstract[24]	new[24]	_	_
5-3	418-419	:	_	_	_	_
5-4	420-429	Utilizing	_	_	_	_
5-5	430-441	Data-Driven	person[25]	new[25]	_	_
5-6	442-448	Models	person[25]	new[25]	_	_
5-7	449-451	in	_	_	_	_
5-8	452-464	Experimental	abstract[26]	new[26]	coref	6-1[27_26]
5-9	465-471	Design	abstract[26]	new[26]	_	_

#Text=Statistical design , also known as design-of-experiments , is arguably the most commonly employed strategy for medium development .
6-1	472-483	Statistical	abstract[27]	giv[27]	coref	6-10[28_27]
6-2	484-490	design	abstract[27]	giv[27]	_	_
6-3	491-492	,	_	_	_	_
6-4	493-497	also	_	_	_	_
6-5	498-503	known	_	_	_	_
6-6	504-506	as	_	_	_	_
6-7	507-528	design-of-experiments	_	_	_	_
6-8	529-530	,	_	_	_	_
6-9	531-533	is	_	_	_	_
6-10	534-542	arguably	abstract[28]	giv[28]	coref	11-7[0_28]
6-11	543-546	the	abstract[28]	giv[28]	_	_
6-12	547-551	most	abstract[28]	giv[28]	_	_
6-13	552-560	commonly	abstract[28]	giv[28]	_	_
6-14	561-569	employed	abstract[28]	giv[28]	_	_
6-15	570-578	strategy	abstract[28]	giv[28]	_	_
6-16	579-582	for	abstract[28]	giv[28]	_	_
6-17	583-589	medium	abstract[28]|event[29]	giv[28]|new[29]	ana	7-13[34_29]
6-18	590-601	development	abstract[28]|event[29]	giv[28]|new[29]	_	_
6-19	602-603	.	_	_	_	_

#Text=Unfortunately most such studies for CHO cells focus on components such as those relevant for the carbon and energy metabolism with only a limited number of studies specifically addressing amino acids .
7-1	604-617	Unfortunately	event[30]	new[30]	coref	7-27[0_30]
7-2	618-622	most	event[30]	new[30]	_	_
7-3	623-627	such	event[30]	new[30]	_	_
7-4	628-635	studies	event[30]	new[30]	_	_
7-5	636-639	for	event[30]	new[30]	_	_
7-6	640-643	CHO	event[30]|substance|object[32]	new[30]|giv|giv[32]	coref|coref|coref|coref	9-18|9-16[59_32]|9-18|9-16[59_32]
7-7	644-649	cells	event[30]|object[32]	new[30]|giv[32]	_	_
7-8	650-655	focus	_	_	_	_
7-9	656-658	on	_	_	_	_
7-10	659-669	components	abstract[33]	new[33]	_	_
7-11	670-674	such	abstract[33]	new[33]	_	_
7-12	675-677	as	abstract[33]	new[33]	_	_
7-13	678-683	those	abstract[33]|event[34]	new[33]|giv[34]	coref	8-19[46_34]
7-14	684-692	relevant	abstract[33]|event[34]	new[33]|giv[34]	_	_
7-15	693-696	for	_	_	_	_
7-16	697-700	the	substance[35]	new[35]	_	_
7-17	701-707	carbon	substance[35]	new[35]	_	_
7-18	708-711	and	_	_	_	_
7-19	712-718	energy	substance|abstract[37]	new|new[37]	coref|coref	12-16[92_37]|12-16[92_37]
7-20	719-729	metabolism	abstract[37]	new[37]	_	_
7-21	730-734	with	abstract[37]	new[37]	_	_
7-22	735-739	only	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
7-23	740-741	a	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
7-24	742-749	limited	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
7-25	750-756	number	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
7-26	757-759	of	abstract[37]|abstract[38]	new[37]|giv[38]	_	_
7-27	760-767	studies	abstract[37]|abstract[38]|event	new[37]|giv[38]|giv	coref	19-6[156_0]
7-28	768-780	specifically	_	_	_	_
7-29	781-791	addressing	_	_	_	_
7-30	792-797	amino	object|substance[41]	giv|giv[41]	coref|coref|coref|coref	10-1[60_0]|11-14[78_41]|10-1[60_0]|11-14[78_41]
7-31	798-803	acids	substance[41]	giv[41]	_	_
7-32	804-805	.	_	_	_	_

#Text=In line with this observation for statistical methodologies , search heuristics such as genetic algorithms commonly employed in medium development and optimization in various organisms have not been utilized for improving CHO cell medium compositions , even the chemically defined cell-free formulations .
8-1	806-808	In	_	_	_	_
8-2	809-813	line	_	_	_	_
8-3	814-818	with	_	_	_	_
8-4	819-823	this	abstract[42]	new[42]	_	_
8-5	824-835	observation	abstract[42]	new[42]	_	_
8-6	836-839	for	abstract[42]	new[42]	_	_
8-7	840-851	statistical	abstract[42]|abstract[43]	new[42]|new[43]	_	_
8-8	852-865	methodologies	abstract[42]|abstract[43]	new[42]|new[43]	_	_
8-9	866-867	,	_	_	_	_
8-10	868-874	search	_	_	_	_
8-11	875-885	heuristics	abstract[44]	new[44]	_	_
8-12	886-890	such	abstract[44]	new[44]	_	_
8-13	891-893	as	abstract[44]	new[44]	_	_
8-14	894-901	genetic	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-15	902-912	algorithms	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-16	913-921	commonly	_	_	_	_
8-17	922-930	employed	_	_	_	_
8-18	931-933	in	_	_	_	_
8-19	934-940	medium	event[46]	giv[46]	coref	20-41[0_46]
8-20	941-952	development	event[46]	giv[46]	_	_
8-21	953-956	and	_	_	_	_
8-22	957-969	optimization	abstract[47]	new[47]	coref	17-13[135_47]
8-23	970-972	in	abstract[47]	new[47]	_	_
8-24	973-980	various	abstract[47]|animal[48]	new[47]|new[48]	_	_
8-25	981-990	organisms	abstract[47]|animal[48]	new[47]|new[48]	_	_
8-26	991-995	have	_	_	_	_
8-27	996-999	not	_	_	_	_
8-28	1000-1004	been	_	_	_	_
8-29	1005-1013	utilized	_	_	_	_
8-30	1014-1017	for	_	_	_	_
8-31	1018-1027	improving	_	_	_	_
8-32	1028-1031	CHO	object[50]	new[50]	_	_
8-33	1032-1036	cell	place|object[50]	new|new[50]	coref	10-31
8-34	1037-1043	medium	object[50]	new[50]	_	_
8-35	1044-1056	compositions	object[50]	new[50]	_	_
8-36	1057-1058	,	_	_	_	_
8-37	1059-1063	even	substance[51]	new[51]	_	_
8-38	1064-1067	the	substance[51]	new[51]	_	_
8-39	1068-1078	chemically	substance[51]	new[51]	_	_
8-40	1079-1086	defined	substance[51]	new[51]	_	_
8-41	1087-1096	cell-free	substance[51]	new[51]	_	_
8-42	1097-1109	formulations	substance[51]	new[51]	_	_
8-43	1110-1111	.	_	_	_	_

#Text=Low glutamine and high essential amino acid concentrations led to high mAb production against Botulinum A by CHO cells .
9-1	1112-1115	Low	substance[52]	new[52]	coref	10-6[0_52]
9-2	1116-1125	glutamine	substance[52]	new[52]	_	_
9-3	1126-1129	and	_	_	_	_
9-4	1130-1134	high	abstract[54]	new[54]	coref	18-25[147_54]
9-5	1135-1144	essential	abstract[54]	new[54]	_	_
9-6	1145-1150	amino	abstract[54]	new[54]	_	_
9-7	1151-1155	acid	substance|abstract[54]	new|new[54]	coref	10-3
9-8	1156-1170	concentrations	abstract[54]	new[54]	_	_
9-9	1171-1174	led	_	_	_	_
9-10	1175-1177	to	_	_	_	_
9-11	1178-1182	high	abstract[56]	new[56]	coref	10-42[71_56]
9-12	1183-1186	mAb	substance|abstract[56]	new|new[56]	coref	23-17
9-13	1187-1197	production	abstract[56]	new[56]	_	_
9-14	1198-1205	against	_	_	_	_
9-15	1206-1215	Botulinum	substance	new	_	_
9-16	1216-1217	A	object[59]	giv[59]	coref	11-27[85_59]
9-17	1218-1220	by	object[59]	giv[59]	_	_
9-18	1221-1224	CHO	substance|object[59]	giv|giv[59]	coref	12-17
9-19	1225-1230	cells	object[59]	giv[59]	_	_
9-20	1231-1232	.	_	_	_	_

#Text=An amino acid other than glutamine ( analytically uncharacterized ) was identified as the limiting component in a study that employed response surface methodology to evaluate medium-associated effects on viable cell density ( as a proxy for mAb concentration ) during coupled production and growth .
10-1	1233-1235	An	object[60]	giv[60]	coref	14-10[0_60]
10-2	1236-1241	amino	object[60]	giv[60]	_	_
10-3	1242-1246	acid	object[60]|substance	giv[60]|giv	coref	15-13
10-4	1247-1252	other	object[60]	giv[60]	_	_
10-5	1253-1257	than	_	_	_	_
10-6	1258-1267	glutamine	substance	giv	_	_
10-7	1268-1269	(	_	_	_	_
10-8	1270-1282	analytically	_	_	_	_
10-9	1283-1298	uncharacterized	_	_	_	_
10-10	1299-1300	)	_	_	_	_
10-11	1301-1304	was	_	_	_	_
10-12	1305-1315	identified	_	_	_	_
10-13	1316-1318	as	_	_	_	_
10-14	1319-1322	the	_	_	_	_
10-15	1323-1331	limiting	_	_	_	_
10-16	1332-1341	component	_	_	_	_
10-17	1342-1344	in	_	_	_	_
10-18	1345-1346	a	abstract[63]	new[63]	coref	19-39[164_63]
10-19	1347-1352	study	abstract[63]	new[63]	_	_
10-20	1353-1357	that	_	_	_	_
10-21	1358-1366	employed	_	_	_	_
10-22	1367-1375	response	abstract|abstract[66]	new|new[66]	coref|coref|coref|coref	18-35|18-35[152_66]|18-35|18-35[152_66]
10-23	1376-1383	surface	place|abstract[66]	new|new[66]	coref	18-36
10-24	1384-1395	methodology	abstract[66]	new[66]	_	_
10-25	1396-1398	to	_	_	_	_
10-26	1399-1407	evaluate	_	_	_	_
10-27	1408-1425	medium-associated	abstract[67]	new[67]	coref	18-13[144_67]
10-28	1426-1433	effects	abstract[67]	new[67]	_	_
10-29	1434-1436	on	abstract[67]	new[67]	_	_
10-30	1437-1443	viable	abstract[67]|abstract[69]	new[67]|new[69]	coref	13-40[103_69]
10-31	1444-1448	cell	abstract[67]|object|abstract[69]	new[67]|giv|new[69]	coref	12-18
10-32	1449-1456	density	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-33	1457-1458	(	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-34	1459-1461	as	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-35	1462-1463	a	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-36	1464-1469	proxy	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-37	1470-1473	for	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-38	1474-1477	mAb	abstract[67]|abstract[69]|abstract[70]	new[67]|new[69]|new[70]	coref	13-20[98_70]
10-39	1478-1491	concentration	abstract[67]|abstract[69]|abstract[70]	new[67]|new[69]|new[70]	_	_
10-40	1492-1493	)	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-41	1494-1500	during	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-42	1501-1508	coupled	abstract[67]|abstract[69]|abstract[71]	new[67]|new[69]|giv[71]	coref	11-23[82_71]
10-43	1509-1519	production	abstract[67]|abstract[69]|abstract[71]	new[67]|new[69]|giv[71]	_	_
10-44	1520-1523	and	abstract[67]|abstract[69]	new[67]|new[69]	_	_
10-45	1524-1530	growth	abstract[67]|abstract[69]|abstract	new[67]|new[69]|new	coref	11-21
10-46	1531-1532	.	_	_	_	_

#Text=González et al. used the Plackett-Burman design method to optimize the contribution of ten amino acids to the rate of growth and monoclonal antibody production by Chinese hamster ovary cells .
11-1	1533-1541	González	person	new	_	_
11-2	1542-1544	et	_	_	_	_
11-3	1545-1548	al.	_	_	_	_
11-4	1549-1553	used	_	_	_	_
11-5	1554-1557	the	abstract[76]	new[76]	coref	23-1[181_76]
11-6	1558-1573	Plackett-Burman	person|abstract[76]	new|new[76]	coref	18-9
11-7	1574-1580	design	abstract|abstract[76]	giv|new[76]	coref	16-4[127_0]
11-8	1581-1587	method	abstract[76]	new[76]	_	_
11-9	1588-1590	to	_	_	_	_
11-10	1591-1599	optimize	_	_	_	_
11-11	1600-1603	the	abstract[77]	new[77]	_	_
11-12	1604-1616	contribution	abstract[77]	new[77]	_	_
11-13	1617-1619	of	abstract[77]	new[77]	_	_
11-14	1620-1623	ten	abstract[77]|substance[78]	new[77]|giv[78]	coref	12-1[86_78]
11-15	1624-1629	amino	abstract[77]|substance[78]	new[77]|giv[78]	_	_
11-16	1630-1635	acids	abstract[77]|substance[78]	new[77]|giv[78]	_	_
11-17	1636-1638	to	abstract[77]	new[77]	_	_
11-18	1639-1642	the	abstract[77]|quantity[79]	new[77]|new[79]	coref	13-15[97_79]
11-19	1643-1647	rate	abstract[77]|quantity[79]	new[77]|new[79]	_	_
11-20	1648-1650	of	abstract[77]|quantity[79]	new[77]|new[79]	_	_
11-21	1651-1657	growth	abstract[77]|quantity[79]|abstract	new[77]|new[79]|giv	coref	13-11
11-22	1658-1661	and	abstract[77]|quantity[79]	new[77]|new[79]	_	_
11-23	1662-1672	monoclonal	abstract[77]|quantity[79]|abstract[82]	new[77]|new[79]|giv[82]	coref	23-17[187_82]
11-24	1673-1681	antibody	abstract[77]|quantity[79]|substance|abstract[82]	new[77]|new[79]|new|giv[82]	coref	13-51
11-25	1682-1692	production	abstract[77]|quantity[79]|abstract[82]	new[77]|new[79]|giv[82]	_	_
11-26	1693-1695	by	abstract[77]|quantity[79]|abstract[82]	new[77]|new[79]|giv[82]	_	_
11-27	1696-1703	Chinese	abstract[77]|quantity[79]|abstract[82]|object[85]	new[77]|new[79]|giv[82]|giv[85]	coref	16-9[128_85]
11-28	1704-1711	hamster	abstract[77]|quantity[79]|abstract[82]|animal|object[85]	new[77]|new[79]|giv[82]|new|giv[85]	_	_
11-29	1712-1717	ovary	abstract[77]|quantity[79]|abstract[82]|person|object[85]	new[77]|new[79]|giv[82]|new|giv[85]	_	_
11-30	1718-1723	cells	abstract[77]|quantity[79]|abstract[82]|object[85]	new[77]|new[79]|giv[82]|giv[85]	_	_
11-31	1724-1725	.	_	_	_	_

#Text=These 10 amino acids were specifically identified as per their superior uptake and utilization by the CHO cell metabolism .
12-1	1726-1731	These	substance[86]	giv[86]	ana	12-10[0_86]
12-2	1732-1734	10	substance[86]	giv[86]	_	_
12-3	1735-1740	amino	substance[86]	giv[86]	_	_
12-4	1741-1746	acids	substance[86]	giv[86]	_	_
12-5	1747-1751	were	_	_	_	_
12-6	1752-1764	specifically	_	_	_	_
12-7	1765-1775	identified	_	_	_	_
12-8	1776-1778	as	_	_	_	_
12-9	1779-1782	per	_	_	_	_
12-10	1783-1788	their	substance|abstract[88]	giv|new[88]	coref|coref	14-8[113_0]|14-8[113_0]
12-11	1789-1797	superior	abstract[88]	new[88]	_	_
12-12	1798-1804	uptake	abstract[88]	new[88]	_	_
12-13	1805-1808	and	_	_	_	_
12-14	1809-1820	utilization	abstract[89]	new[89]	coref	20-26[174_89]
12-15	1821-1823	by	abstract[89]	new[89]	_	_
12-16	1824-1827	the	abstract[89]|abstract[92]	new[89]|giv[92]	_	_
12-17	1828-1831	CHO	abstract[89]|object|abstract[92]	new[89]|giv|giv[92]	_	_
12-18	1832-1836	cell	abstract[89]|object|abstract[92]	new[89]|giv|giv[92]	coref	13-25
12-19	1837-1847	metabolism	abstract[89]|abstract[92]	new[89]|giv[92]	_	_
12-20	1848-1849	.	_	_	_	_

#Text=The analysis was carried out both during exponential phase of growth through monitoring how the specific growth rate and the concentration of the viable cell concentration evolved over time , and during the phase where the cell population reached a very high density , through monitoring of the final monoclonal antibody product concentration and the specific productivity of the cell population .
13-1	1850-1853	The	abstract[93]	new[93]	_	_
13-2	1854-1862	analysis	abstract[93]	new[93]	_	_
13-3	1863-1866	was	_	_	_	_
13-4	1867-1874	carried	_	_	_	_
13-5	1875-1878	out	_	_	_	_
13-6	1879-1883	both	abstract[94]	new[94]	coref	13-33[100_94]
13-7	1884-1890	during	abstract[94]	new[94]	_	_
13-8	1891-1902	exponential	abstract[94]	new[94]	_	_
13-9	1903-1908	phase	abstract[94]	new[94]	_	_
13-10	1909-1911	of	abstract[94]	new[94]	_	_
13-11	1912-1918	growth	abstract[94]|abstract	new[94]|giv	coref	13-17
13-12	1919-1926	through	_	_	_	_
13-13	1927-1937	monitoring	_	_	_	_
13-14	1938-1941	how	_	_	_	_
13-15	1942-1945	the	quantity[97]	giv[97]	_	_
13-16	1946-1954	specific	quantity[97]	giv[97]	_	_
13-17	1955-1961	growth	abstract|quantity[97]	giv|giv[97]	_	_
13-18	1962-1966	rate	quantity[97]	giv[97]	_	_
13-19	1967-1970	and	_	_	_	_
13-20	1971-1974	the	abstract[98]	giv[98]	coref	13-48[107_98]
13-21	1975-1988	concentration	abstract[98]	giv[98]	_	_
13-22	1989-1991	of	abstract[98]	giv[98]	_	_
13-23	1992-1995	the	abstract[98]	giv[98]	_	_
13-24	1996-2002	viable	abstract[98]	giv[98]	_	_
13-25	2003-2007	cell	abstract[98]|place	giv[98]|giv	coref	13-37
13-26	2008-2021	concentration	abstract[98]	giv[98]	_	_
13-27	2022-2029	evolved	_	_	_	_
13-28	2030-2034	over	_	_	_	_
13-29	2035-2039	time	_	_	_	_
13-30	2040-2041	,	_	_	_	_
13-31	2042-2045	and	_	_	_	_
13-32	2046-2052	during	_	_	_	_
13-33	2053-2056	the	abstract[100]	giv[100]	_	_
13-34	2057-2062	phase	abstract[100]	giv[100]	_	_
13-35	2063-2068	where	_	_	_	_
13-36	2069-2072	the	abstract[102]	new[102]	coref	13-59[110_102]
13-37	2073-2077	cell	place|abstract[102]	giv|new[102]	coref	13-60
13-38	2078-2088	population	abstract[102]	new[102]	_	_
13-39	2089-2096	reached	_	_	_	_
13-40	2097-2098	a	abstract[103]	giv[103]	_	_
13-41	2099-2103	very	abstract[103]	giv[103]	_	_
13-42	2104-2108	high	abstract[103]	giv[103]	_	_
13-43	2109-2116	density	abstract[103]	giv[103]	_	_
13-44	2117-2118	,	_	_	_	_
13-45	2119-2126	through	_	_	_	_
13-46	2127-2137	monitoring	event[104]	new[104]	_	_
13-47	2138-2140	of	event[104]	new[104]	_	_
13-48	2141-2144	the	event[104]|abstract[107]	new[104]|giv[107]	_	_
13-49	2145-2150	final	event[104]|abstract[107]	new[104]|giv[107]	_	_
13-50	2151-2161	monoclonal	event[104]|abstract[107]	new[104]|giv[107]	_	_
13-51	2162-2170	antibody	event[104]|substance|abstract[107]	new[104]|giv|giv[107]	_	_
13-52	2171-2178	product	event[104]|substance|abstract[107]	new[104]|new|giv[107]	coref	14-22
13-53	2179-2192	concentration	event[104]|abstract[107]	new[104]|giv[107]	_	_
13-54	2193-2196	and	event[104]	new[104]	_	_
13-55	2197-2200	the	event[104]|abstract[108]	new[104]|new[108]	_	_
13-56	2201-2209	specific	event[104]|abstract[108]	new[104]|new[108]	_	_
13-57	2210-2222	productivity	event[104]|abstract[108]	new[104]|new[108]	_	_
13-58	2223-2225	of	event[104]|abstract[108]	new[104]|new[108]	_	_
13-59	2226-2229	the	event[104]|abstract[108]|abstract[110]	new[104]|new[108]|giv[110]	coref	17-25[140_110]
13-60	2230-2234	cell	event[104]|abstract[108]|place|abstract[110]	new[104]|new[108]|giv|giv[110]	coref	17-8
13-61	2235-2245	population	event[104]|abstract[108]|abstract[110]	new[104]|new[108]|giv[110]	_	_
13-62	2246-2247	.	_	_	_	_

#Text=This investigation aimed to determine which among the ten amino acids were critical for supporting health growth of the population and product formation .
14-1	2248-2252	This	event[111]	new[111]	_	_
14-2	2253-2266	investigation	event[111]	new[111]	_	_
14-3	2267-2272	aimed	_	_	_	_
14-4	2273-2275	to	_	_	_	_
14-5	2276-2285	determine	_	_	_	_
14-6	2286-2291	which	_	_	_	_
14-7	2292-2297	among	_	_	_	_
14-8	2298-2301	the	substance[113]	giv[113]	coref	16-12[130_113]
14-9	2302-2305	ten	substance[113]	giv[113]	_	_
14-10	2306-2311	amino	object|substance[113]	giv|giv[113]	coref	16-14
14-11	2312-2317	acids	substance[113]	giv[113]	_	_
14-12	2318-2322	were	_	_	_	_
14-13	2323-2331	critical	_	_	_	_
14-14	2332-2335	for	_	_	_	_
14-15	2336-2346	supporting	_	_	_	_
14-16	2347-2353	health	abstract|abstract[115]	new|new[115]	coref|coref	17-13[0_115]|17-13[0_115]
14-17	2354-2360	growth	abstract[115]	new[115]	_	_
14-18	2361-2363	of	abstract[115]	new[115]	_	_
14-19	2364-2367	the	abstract[115]|person[116]	new[115]|new[116]	_	_
14-20	2368-2378	population	abstract[115]|person[116]	new[115]|new[116]	_	_
14-21	2379-2382	and	abstract[115]	new[115]	_	_
14-22	2383-2390	product	abstract[115]|abstract|abstract[118]	new[115]|giv|new[118]	coref|coref|coref|coref	17-22|17-22[138_118]|17-22|17-22[138_118]
14-23	2391-2400	formation	abstract[115]|abstract[118]	new[115]|new[118]	_	_
14-24	2401-2402	.	_	_	_	_

#Text=In return , this information could be utilized for designing an amino acid supplementation regime , through which a superior culture could be achieved through medium improvements .
15-1	2403-2405	In	_	_	_	_
15-2	2406-2412	return	event	new	_	_
15-3	2413-2414	,	_	_	_	_
15-4	2415-2419	this	abstract[120]	new[120]	_	_
15-5	2420-2431	information	abstract[120]	new[120]	_	_
15-6	2432-2437	could	_	_	_	_
15-7	2438-2440	be	_	_	_	_
15-8	2441-2449	utilized	_	_	_	_
15-9	2450-2453	for	_	_	_	_
15-10	2454-2463	designing	_	_	_	_
15-11	2464-2466	an	abstract[123]	new[123]	_	_
15-12	2467-2472	amino	abstract[123]	new[123]	_	_
15-13	2473-2477	acid	substance|abstract[123]	giv|new[123]	coref	23-14
15-14	2478-2493	supplementation	abstract|abstract[123]	new|new[123]	_	_
15-15	2494-2500	regime	abstract[123]	new[123]	_	_
15-16	2501-2502	,	_	_	_	_
15-17	2503-2510	through	_	_	_	_
15-18	2511-2516	which	_	_	_	_
15-19	2517-2518	a	abstract[124]	giv[124]	coref	17-6[133_124]
15-20	2519-2527	superior	abstract[124]	giv[124]	_	_
15-21	2528-2535	culture	abstract[124]	giv[124]	_	_
15-22	2536-2541	could	_	_	_	_
15-23	2542-2544	be	_	_	_	_
15-24	2545-2553	achieved	_	_	_	_
15-25	2554-2561	through	_	_	_	_
15-26	2562-2568	medium	abstract[125]	new[125]	_	_
15-27	2569-2581	improvements	abstract[125]	new[125]	_	_
15-28	2582-2583	.	_	_	_	_

#Text=The authors proposed a two-stage strategy for providing the cells with the key amino acids .
16-1	2584-2587	The	person[126]	new[126]	_	_
16-2	2588-2595	authors	person[126]	new[126]	_	_
16-3	2596-2604	proposed	_	_	_	_
16-4	2605-2606	a	abstract[127]	giv[127]	coref	18-8[143_127]
16-5	2607-2616	two-stage	abstract[127]	giv[127]	_	_
16-6	2617-2625	strategy	abstract[127]	giv[127]	_	_
16-7	2626-2629	for	_	_	_	_
16-8	2630-2639	providing	_	_	_	_
16-9	2640-2643	the	object[128]	giv[128]	_	_
16-10	2644-2649	cells	object[128]	giv[128]	_	_
16-11	2650-2654	with	object[128]	giv[128]	_	_
16-12	2655-2658	the	object[128]|substance[130]	giv[128]|giv[130]	coref	18-16[145_130]
16-13	2659-2662	key	object[128]|substance[130]	giv[128]|giv[130]	_	_
16-14	2663-2668	amino	object[128]|object|substance[130]	giv[128]|giv|giv[130]	_	_
16-15	2669-2674	acids	object[128]|substance[130]	giv[128]|giv[130]	_	_
16-16	2675-2676	.	_	_	_	_

#Text=One stage focused on achieving a healthy cell culture through focusing on growth optimization , and a second stage which optimizes product formation once a large cell population has been achieved .
17-1	2677-2680	One	abstract[131]	new[131]	coref	17-17[136_131]
17-2	2681-2686	stage	abstract[131]	new[131]	_	_
17-3	2687-2694	focused	_	_	_	_
17-4	2695-2697	on	_	_	_	_
17-5	2698-2707	achieving	_	_	_	_
17-6	2708-2709	a	abstract[133]	giv[133]	_	_
17-7	2710-2717	healthy	abstract[133]	giv[133]	_	_
17-8	2718-2722	cell	place|abstract[133]	giv|giv[133]	coref	17-27
17-9	2723-2730	culture	abstract[133]	giv[133]	_	_
17-10	2731-2738	through	_	_	_	_
17-11	2739-2747	focusing	_	_	_	_
17-12	2748-2750	on	_	_	_	_
17-13	2751-2757	growth	abstract|abstract[135]	giv|giv[135]	coref|coref	18-20|18-20
17-14	2758-2770	optimization	abstract[135]	giv[135]	_	_
17-15	2771-2772	,	_	_	_	_
17-16	2773-2776	and	_	_	_	_
17-17	2777-2778	a	abstract[136]	giv[136]	_	_
17-18	2779-2785	second	abstract[136]	giv[136]	_	_
17-19	2786-2791	stage	abstract[136]	giv[136]	_	_
17-20	2792-2797	which	_	_	_	_
17-21	2798-2807	optimizes	_	_	_	_
17-22	2808-2815	product	abstract|abstract[138]	giv|giv[138]	_	_
17-23	2816-2825	formation	abstract[138]	giv[138]	_	_
17-24	2826-2830	once	_	_	_	_
17-25	2831-2832	a	abstract[140]	giv[140]	_	_
17-26	2833-2838	large	abstract[140]	giv[140]	_	_
17-27	2839-2843	cell	place|abstract[140]	giv|giv[140]	_	_
17-28	2844-2854	population	abstract[140]	giv[140]	_	_
17-29	2855-2858	has	_	_	_	_
17-30	2859-2863	been	_	_	_	_
17-31	2864-2872	achieved	_	_	_	_
17-32	2873-2874	.	_	_	_	_

#Text=More recently , Torkashvand et al. used the Plackett-Burman design to screen the effects of amino acids on promoting growth , and then optimized the medium concentrations of a combination of amino acids using response surface methodology to determine the feed composition .
18-1	2875-2879	More	_	_	_	_
18-2	2880-2888	recently	_	_	_	_
18-3	2889-2890	,	_	_	_	_
18-4	2891-2902	Torkashvand	person	new	_	_
18-5	2903-2905	et	_	_	_	_
18-6	2906-2909	al.	_	_	_	_
18-7	2910-2914	used	_	_	_	_
18-8	2915-2918	the	abstract[143]	giv[143]	coref	19-28[0_143]
18-9	2919-2934	Plackett-Burman	person|abstract[143]	giv|giv[143]	_	_
18-10	2935-2941	design	abstract[143]	giv[143]	_	_
18-11	2942-2944	to	_	_	_	_
18-12	2945-2951	screen	_	_	_	_
18-13	2952-2955	the	abstract[144]	giv[144]	_	_
18-14	2956-2963	effects	abstract[144]	giv[144]	_	_
18-15	2964-2966	of	abstract[144]	giv[144]	_	_
18-16	2967-2972	amino	abstract[144]|substance[145]	giv[144]|giv[145]	coref	18-32[149_145]
18-17	2973-2978	acids	abstract[144]|substance[145]	giv[144]|giv[145]	_	_
18-18	2979-2981	on	_	_	_	_
18-19	2982-2991	promoting	_	_	_	_
18-20	2992-2998	growth	abstract	giv	_	_
18-21	2999-3000	,	_	_	_	_
18-22	3001-3004	and	_	_	_	_
18-23	3005-3009	then	_	_	_	_
18-24	3010-3019	optimized	_	_	_	_
18-25	3020-3023	the	abstract[147]	giv[147]	_	_
18-26	3024-3030	medium	abstract[147]	giv[147]	_	_
18-27	3031-3045	concentrations	abstract[147]	giv[147]	_	_
18-28	3046-3048	of	abstract[147]	giv[147]	_	_
18-29	3049-3050	a	abstract[147]|abstract[148]	giv[147]|new[148]	_	_
18-30	3051-3062	combination	abstract[147]|abstract[148]	giv[147]|new[148]	_	_
18-31	3063-3065	of	abstract[147]|abstract[148]	giv[147]|new[148]	_	_
18-32	3066-3071	amino	abstract[147]|abstract[148]|substance[149]	giv[147]|new[148]|giv[149]	_	_
18-33	3072-3077	acids	abstract[147]|abstract[148]|substance[149]	giv[147]|new[148]|giv[149]	_	_
18-34	3078-3083	using	_	_	_	_
18-35	3084-3092	response	abstract|abstract[152]	giv|giv[152]	_	_
18-36	3093-3100	surface	place|abstract[152]	giv|giv[152]	_	_
18-37	3101-3112	methodology	abstract[152]	giv[152]	_	_
18-38	3113-3115	to	_	_	_	_
18-39	3116-3125	determine	_	_	_	_
18-40	3126-3129	the	abstract[154]	giv[154]	coref	23-13[185_154]
18-41	3130-3134	feed	substance|abstract[154]	new|giv[154]	_	_
18-42	3135-3146	composition	abstract[154]	giv[154]	_	_
18-43	3147-3148	.	_	_	_	_

#Text=Although statistics were employed in these studies , it would be very difficult to extract learning as to the nature of the potential benefits of employing different design approaches since these investigations focused on the empirical aspects of the study rather than providing an in-depth evaluation of the statistical tools employed .
19-1	3149-3157	Although	_	_	_	_
19-2	3158-3168	statistics	abstract	new	_	_
19-3	3169-3173	were	_	_	_	_
19-4	3174-3182	employed	_	_	_	_
19-5	3183-3185	in	_	_	_	_
19-6	3186-3191	these	event[156]	giv[156]	_	_
19-7	3192-3199	studies	event[156]	giv[156]	_	_
19-8	3200-3201	,	_	_	_	_
19-9	3202-3204	it	substance	new	cata	19-9[0_158]
19-10	3205-3210	would	_	_	_	_
19-11	3211-3213	be	_	_	_	_
19-12	3214-3218	very	_	_	_	_
19-13	3219-3228	difficult	_	_	_	_
19-14	3229-3231	to	substance[158]	new[158]	_	_
19-15	3232-3239	extract	substance[158]	new[158]	_	_
19-16	3240-3248	learning	substance[158]	new[158]	_	_
19-17	3249-3251	as	_	_	_	_
19-18	3252-3254	to	_	_	_	_
19-19	3255-3258	the	_	_	_	_
19-20	3259-3265	nature	_	_	_	_
19-21	3266-3268	of	_	_	_	_
19-22	3269-3272	the	abstract[159]	new[159]	_	_
19-23	3273-3282	potential	abstract[159]	new[159]	_	_
19-24	3283-3291	benefits	abstract[159]	new[159]	_	_
19-25	3292-3294	of	_	_	_	_
19-26	3295-3304	employing	_	_	_	_
19-27	3305-3314	different	abstract[161]	new[161]	_	_
19-28	3315-3321	design	abstract|abstract[161]	giv|new[161]	_	_
19-29	3322-3332	approaches	abstract[161]	new[161]	_	_
19-30	3333-3338	since	_	_	_	_
19-31	3339-3344	these	abstract[162]	new[162]	_	_
19-32	3345-3359	investigations	abstract[162]	new[162]	_	_
19-33	3360-3367	focused	_	_	_	_
19-34	3368-3370	on	_	_	_	_
19-35	3371-3374	the	abstract[163]	new[163]	_	_
19-36	3375-3384	empirical	abstract[163]	new[163]	_	_
19-37	3385-3392	aspects	abstract[163]	new[163]	_	_
19-38	3393-3395	of	abstract[163]	new[163]	_	_
19-39	3396-3399	the	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
19-40	3400-3405	study	abstract[163]|abstract[164]	new[163]|giv[164]	_	_
19-41	3406-3412	rather	_	_	_	_
19-42	3413-3417	than	_	_	_	_
19-43	3418-3427	providing	_	_	_	_
19-44	3428-3430	an	abstract[165]	new[165]	_	_
19-45	3431-3439	in-depth	abstract[165]	new[165]	_	_
19-46	3440-3450	evaluation	abstract[165]	new[165]	_	_
19-47	3451-3453	of	abstract[165]	new[165]	_	_
19-48	3454-3457	the	abstract[165]|abstract[166]	new[165]|new[166]	ana	20-3[0_166]
19-49	3458-3469	statistical	abstract[165]|abstract[166]	new[165]|new[166]	_	_
19-50	3470-3475	tools	abstract[165]|abstract[166]	new[165]|new[166]	_	_
19-51	3476-3484	employed	_	_	_	_
19-52	3485-3486	.	_	_	_	_

#Text=Consequently , they fail to compare and contrast different methods and provide reasoning for the selection of certain models over others , or point towards the utilization of favorable statistical designs , which could prove invaluable to attain systematic medium development strategies .
20-1	3487-3499	Consequently	_	_	_	_
20-2	3500-3501	,	_	_	_	_
20-3	3502-3506	they	abstract	giv	_	_
20-4	3507-3511	fail	_	_	_	_
20-5	3512-3514	to	_	_	_	_
20-6	3515-3522	compare	_	_	_	_
20-7	3523-3526	and	_	_	_	_
20-8	3527-3535	contrast	_	_	_	_
20-9	3536-3545	different	abstract[168]	giv[168]	coref	24-1[189_168]
20-10	3546-3553	methods	abstract[168]	giv[168]	_	_
20-11	3554-3557	and	_	_	_	_
20-12	3558-3565	provide	_	_	_	_
20-13	3566-3575	reasoning	abstract[169]	new[169]	_	_
20-14	3576-3579	for	abstract[169]	new[169]	_	_
20-15	3580-3583	the	abstract[169]|abstract[170]	new[169]|new[170]	_	_
20-16	3584-3593	selection	abstract[169]|abstract[170]	new[169]|new[170]	_	_
20-17	3594-3596	of	abstract[169]|abstract[170]	new[169]|new[170]	_	_
20-18	3597-3604	certain	abstract[169]|abstract[170]|abstract[171]	new[169]|new[170]|new[171]	_	_
20-19	3605-3611	models	abstract[169]|abstract[170]|abstract[171]	new[169]|new[170]|new[171]	_	_
20-20	3612-3616	over	abstract[169]|abstract[170]|abstract[171]	new[169]|new[170]|new[171]	_	_
20-21	3617-3623	others	abstract[169]|abstract[170]|abstract[171]|person	new[169]|new[170]|new[171]|new	_	_
20-22	3624-3625	,	abstract[169]|abstract[170]	new[169]|new[170]	_	_
20-23	3626-3628	or	abstract[169]|abstract[170]	new[169]|new[170]	_	_
20-24	3629-3634	point	abstract[169]|abstract[170]|abstract[173]	new[169]|new[170]|new[173]	_	_
20-25	3635-3642	towards	abstract[169]|abstract[170]|abstract[173]	new[169]|new[170]|new[173]	_	_
20-26	3643-3646	the	abstract[169]|abstract[170]|abstract[173]|abstract[174]	new[169]|new[170]|new[173]|giv[174]	_	_
20-27	3647-3658	utilization	abstract[169]|abstract[170]|abstract[173]|abstract[174]	new[169]|new[170]|new[173]|giv[174]	_	_
20-28	3659-3661	of	abstract[169]|abstract[170]|abstract[173]|abstract[174]	new[169]|new[170]|new[173]|giv[174]	_	_
20-29	3662-3671	favorable	abstract[169]|abstract[170]|abstract[173]|abstract[174]|abstract[175]	new[169]|new[170]|new[173]|giv[174]|new[175]	_	_
20-30	3672-3683	statistical	abstract[169]|abstract[170]|abstract[173]|abstract[174]|abstract[175]	new[169]|new[170]|new[173]|giv[174]|new[175]	_	_
20-31	3684-3691	designs	abstract[169]|abstract[170]|abstract[173]|abstract[174]|abstract[175]	new[169]|new[170]|new[173]|giv[174]|new[175]	_	_
20-32	3692-3693	,	_	_	_	_
20-33	3694-3699	which	_	_	_	_
20-34	3700-3705	could	_	_	_	_
20-35	3706-3711	prove	_	_	_	_
20-36	3712-3722	invaluable	_	_	_	_
20-37	3723-3725	to	_	_	_	_
20-38	3726-3732	attain	_	_	_	_
20-39	3733-3743	systematic	abstract[177]	new[177]	_	_
20-40	3744-3750	medium	abstract[177]	new[177]	_	_
20-41	3751-3762	development	event|abstract[177]	giv|new[177]	_	_
20-42	3763-3773	strategies	abstract[177]	new[177]	_	_
20-43	3774-3775	.	_	_	_	_

#Text=2.2 .
21-1	3776-3779	2.2	abstract	new	_	_
21-2	3780-3781	.	_	_	_	_

#Text=Metabolic Profiling
22-1	3782-3791	Metabolic	person|event[180]	new|new[180]	_	_
22-2	3792-3801	Profiling	event[180]	new[180]	_	_

#Text=Another method widely used in the industry to understand the impact of amino acid composition on mAb production is exo- and endo-metabolic profiling .
23-1	3802-3809	Another	abstract[181]	giv[181]	coref	23-20[188_181]
23-2	3810-3816	method	abstract[181]	giv[181]	_	_
23-3	3817-3823	widely	_	_	_	_
23-4	3824-3828	used	_	_	_	_
23-5	3829-3831	in	_	_	_	_
23-6	3832-3835	the	abstract[182]	new[182]	_	_
23-7	3836-3844	industry	abstract[182]	new[182]	_	_
23-8	3845-3847	to	_	_	_	_
23-9	3848-3858	understand	_	_	_	_
23-10	3859-3862	the	abstract[183]	new[183]	_	_
23-11	3863-3869	impact	abstract[183]	new[183]	_	_
23-12	3870-3872	of	abstract[183]	new[183]	_	_
23-13	3873-3878	amino	abstract[183]|abstract[185]	new[183]|giv[185]	_	_
23-14	3879-3883	acid	abstract[183]|substance|abstract[185]	new[183]|giv|giv[185]	_	_
23-15	3884-3895	composition	abstract[183]|abstract[185]	new[183]|giv[185]	_	_
23-16	3896-3898	on	abstract[183]|abstract[185]	new[183]|giv[185]	_	_
23-17	3899-3902	mAb	abstract[183]|abstract[185]|substance|abstract[187]	new[183]|giv[185]|giv|giv[187]	_	_
23-18	3903-3913	production	abstract[183]|abstract[185]|abstract[187]	new[183]|giv[185]|giv[187]	_	_
23-19	3914-3916	is	_	_	_	_
23-20	3917-3921	exo-	abstract[188]	giv[188]	_	_
23-21	3922-3925	and	abstract[188]	giv[188]	_	_
23-22	3926-3940	endo-metabolic	abstract[188]	giv[188]	_	_
23-23	3941-3950	profiling	abstract[188]	giv[188]	_	_
23-24	3951-3952	.	_	_	_	_

#Text=Such methods are purely empirical and are mainly utilized to improve an established platform process , by suggesting specific nutrients to be added during the course of a cultivation , for example , rather than to conduct a broad de novo exploration .
24-1	3953-3957	Such	abstract[189]	giv[189]	_	_
24-2	3958-3965	methods	abstract[189]	giv[189]	_	_
24-3	3966-3969	are	_	_	_	_
24-4	3970-3976	purely	_	_	_	_
24-5	3977-3986	empirical	_	_	_	_
24-6	3987-3990	and	_	_	_	_
24-7	3991-3994	are	_	_	_	_
24-8	3995-4001	mainly	_	_	_	_
24-9	4002-4010	utilized	_	_	_	_
24-10	4011-4013	to	_	_	_	_
24-11	4014-4021	improve	_	_	_	_
24-12	4022-4024	an	abstract[191]	new[191]	_	_
24-13	4025-4036	established	abstract[191]	new[191]	_	_
24-14	4037-4045	platform	abstract|abstract[191]	new|new[191]	_	_
24-15	4046-4053	process	abstract[191]	new[191]	_	_
24-16	4054-4055	,	_	_	_	_
24-17	4056-4058	by	_	_	_	_
24-18	4059-4069	suggesting	_	_	_	_
24-19	4070-4078	specific	substance[192]	new[192]	_	_
24-20	4079-4088	nutrients	substance[192]	new[192]	_	_
24-21	4089-4091	to	_	_	_	_
24-22	4092-4094	be	_	_	_	_
24-23	4095-4100	added	_	_	_	_
24-24	4101-4107	during	_	_	_	_
24-25	4108-4111	the	abstract[193]	new[193]	_	_
24-26	4112-4118	course	abstract[193]	new[193]	_	_
24-27	4119-4121	of	abstract[193]	new[193]	_	_
24-28	4122-4123	a	abstract[193]|event[194]	new[193]|new[194]	_	_
24-29	4124-4135	cultivation	abstract[193]|event[194]	new[193]|new[194]	_	_
24-30	4136-4137	,	_	_	_	_
24-31	4138-4141	for	_	_	_	_
24-32	4142-4149	example	_	_	_	_
24-33	4150-4151	,	_	_	_	_
24-34	4152-4158	rather	_	_	_	_
24-35	4159-4163	than	_	_	_	_
24-36	4164-4166	to	_	_	_	_
24-37	4167-4174	conduct	_	_	_	_
24-38	4175-4176	a	event[195]	new[195]	_	_
24-39	4177-4182	broad	event[195]	new[195]	_	_
24-40	4183-4185	de	event[195]	new[195]	_	_
24-41	4186-4190	novo	event[195]	new[195]	_	_
24-42	4191-4202	exploration	event[195]	new[195]	_	_
24-43	4203-4204	.	_	_	_	_
